Validating novel synthetically lethal vulnerabilities in lung cancer

LIMD1 （LIM结构域含1）是一种肿瘤抑制基因，在非小细胞肺癌（NSCLC）的早期阶段经常丢失，导致LIMD1缺陷患者的预后更差。大约50%的NSCLC病例中存在LIMD1缺陷，在英国至少有21,000例患者，在全球范围内有120万例患者。我们的实验室与CRUK功能基因组中心合作，进行了全基因组CRISPR-Cas9功能基因组筛选，以确定limd1缺陷肺癌细胞的新脆弱性，以便为这部分非小细胞肺癌患者开发个性化治疗。在limd1缺陷细胞中，筛选结果显示与硒代半胱氨酸- trna生物合成和硒代半胱氨酸结合相关的基因显著富集。值得注意的是，唯一确定含有硒代半胱氨酸的酶是GPX4，它可以解毒脂质过氧化物并保护细胞免于铁凋亡。因此，我们假设早期LIMD1缺失可能影响肺癌细胞对铁下垂的敏感性或耐药性。我们的目标包括验证GPX4在limd1缺陷肺癌细胞中的新易感性，在更大范围的肺癌细胞系中评估对铁下垂的敏感性或耐药性，并阐明limd1缺陷细胞中调节铁下垂敏感性或耐药性的机制。使用sirna介导的方法降低GPX4水平，我们的研究结果表明limd1缺陷细胞比limd1精通细胞更敏感。此外，当使用诱导凋亡的化合物RSL3和erastin处理时，limd1缺陷细胞比limd1充足细胞更敏感。我们的实验室正在探索LIMD1在肺癌生物学中尚未实现的潜力，我们希望这将为大量患者带来靶向癌症治疗的革命性进展。”

"LIMD1 (LIM domains containing 1) is a tumour suppressor gene frequently lost during the early stages of non-small cell lung cancer (NSCLC), resulting in a worse outcome for LIMD1-deficient patients.LIMD1 deficiency is present in approximately fifty percent of NSCLC cases, representing at least 21,000 patients in the United Kingdom and 1.2 million worldwide. Our lab, in collaboration with the CRUK Functional Genomic Centre, conducted a whole genome CRISPR-Cas9 functional genomic screen to identify novel vulnerabilities in LIMD1-deficient lung cancer cells in order to develop personalised treatments for this subset of NSCLC patients.In LIMD1-deficient cells, the screen revealed a significant enrichment of genes involved in selenocysteinyl-tRNA biosynthesis and selenocysteine incorporation as novel dependencies. Notably, the only enzyme identified to contain selenocysteine was GPX4, which detoxifies lipid peroxides and protects cells from ferroptosis. We therefore hypothesise that early LIMD1 loss may influence lung cancer cell sensitivity or resistance to ferroptosis.Our goals include validating GPX4 as a novel vulnerability in LIMD1-deficient lung cancer cells, assessing sensitivity or resistance to ferroptosis in a larger panel of lung cancer cell lines, and elucidating the mechanisms that regulate sensitivity or resistance to ferroptosis in LIMD1-deficient cells. Using a siRNA-mediated method to reduce GPX4 levels, our findings indicate that LIMD1-deficient cells are more sensitive than LIMD1-proficient cells. In addition, when treated with ferroptosis-inducing compounds RSL3 and erastin, LIMD1-deficient cells were more sensitive than LIMD1-sufficient cells.Our lab is exploring the unrealised potential of LIMD1 in the biology of lung cancer, and we hope this will lead to revolutionary advances in targeted cancer treatments for a significant subset of patients."